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Abstract
Wnt/ß-catenin signaling is strongly implicated in neoplasia, but the role of this pathway in human breast cancer has been
controversial. Here, we examined Wnt/ß-catenin pathway activation as a function of breast cancer progression, and tested
for a relationship with HER2/neu expression, using a human tissue microarray comprising benign breast tissues, ductal
carcinoma in situ (DCIS), and invasive carcinomas. Cores were scored for membranous ß-catenin, a key functional
component of adherens junctions, and for nucleocytoplasmic ß-catenin, a hallmark of Wnt/ß-catenin pathway activation.
Only 82% of benign samples exhibited membrane-associated ß-catenin, indicating a finite frequency of false-negative
staining. The frequency of membrane positivity was similar in DCIS samples, but was significantly reduced in carcinomas
(45%, P,0.001), consistent with loss of adherens junctions during acquisition of invasiveness. Negative membrane status in
cancers correlated with higher grade (P=0.04) and estrogen receptor-negative status (P=0.03), both indices of poor
prognosis. Unexpectedly, a substantial frequency of nucleocytoplasmic ß-catenin was observed in benign breast tissues
(36%), similar to that in carcinomas (35%). Positive-staining basal nuclei observed in benign breast may identify putative
stem cells. An increased frequency of nucleocytoplasmic ß-catenin was observed in DCIS tumors (56%), suggesting that
pathway activation may be an early event in human breast neoplasia. A correlation was observed between HER2/neu
expression and nucleocytoplasmic ß-catenin in node-positive carcinomas (P=0.02). Furthermore, cytoplasmic ß-catenin was
detected in HER2/neu-induced mouse mammary tumors. The Axin2
NLSlacZ mouse strain, a previously validated reporter of
mammary Wnt/ß-catenin signaling, was utilized to define in vivo transcriptional consequences of HER2/neu-induced ß-
catenin accumulation. Discrete hyperplastic foci observed in mammary glands from bigenic MMTV/neu, Axin2
NLSlacZ mice,
highlighted by robust ß-catenin/TCF signaling, likely represent the earliest stage of mammary intraepithelial neoplasia in
MMTV/neu mice. Our study thus provides provocative evidence for Wnt/ß-catenin signaling as an early, HER2/neu-inducible
event in breast neoplasia.
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Introduction
The goal of this study was to investigate the activation status of
Wnt/ß-catenin signaling in human breast neoplasia, and to test for
a potential relationship between Wnt/ß-catenin pathway activa-
tion and expression of human epidermal growth factor receptor 2
(HER2/neu). ß-catenin protein exists in two discrete functional
pools in epithelial cells. Membrane-associated ß-catenin is an
integral component of the adherens junctions linking membrane-
localized E-cadherin to the actin cytoskeleton via alpha-catenin. In
contrast, ß-catenin protein accumulates in the cytoplasm and
nucleus in response to canonical Wnt signaling, the best
characterized pathway regulated by Wnt proteins [1]. Thus the
presence of nucleocytoplasmic ß-catenin is considered a hallmark
of canonical Wnt pathway activation. Stabilized ß-catenin drives
transcriptional activation of multiple protumorigenic genes via
interaction with TCF/Lef family transcription factors (http://
www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes). The
key role of Wnt/ß-catenin signaling in stem cell biology provides
another mechanism by which this signaling axis may impact
tumorigenesis [2,3].
The role of Wnt/ß-catenin signaling in human breast cancer
has been subject to much debate [4,5]. The first mammalian Wnt
gene, Wnt1, was originally identified as a locus activated by
retroviral insertion of mouse mammary tumor virus (MMTV), and
transgenic Wnt1 overexpression was subsequently shown to drive
mammary tumor formation in mice [6–9]. However, historical
failure to identify substantial frequencies of Wnt ligand overex-
pression in human breast tumors hindered appreciation of the
relevance of Wnt signaling to the human disease. Renewed interest
followed the identification of ß-catenin/TCF complexes as
functional mediators of Wnt-induced transcription.
Striking frequencies of aberrant nucleocytoplasmic ß-catenin
accumulation have now been recorded in multiple human
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elucidation of the likely contribution of Wnt ligand overexpression
to pathway activation in human cancer specimens has been
hampered by a dearth of immunohistochemistry-compatible anti-
Wnt antibodies. However, mutation of pathway components,
including the APC, Axin, and CTNNB1 genes (encoding ß-catenin),
leading to ß-catenin stabilization, and hence activation of the
Wnt/ß-catenin pathway, is now recognized as a common event in
human tumorigenesis [10,11]. Because such mutations are
comparatively rare in human breast carcinomas, excepting
fibromatoses and metaplastic tumors [12–21], multiple groups
have sought evidence of pathway activation by interrogating the
subcellular localization of ß-catenin protein in human breast
cancers. Conflicting results from these predominantly immuno-
histochemical studies have again kindled controversy, with some
groups reporting that high proportions of breast cancers have
nucleocytoplasmic ß-catenin [22–28] but other investigators failing
to detect substantial frequencies [29]. Further confusion emanates
from several studies which elected not to separately assess the
functionally distinct membrane and nucleocytoplasmic ß-catenin
pools [30–32].
Our goal in the present study was to further investigate the
frequency of Wnt/ß-catenin signaling pathway activation in breast
neoplasia using ß-catenin immunohistochemistry (IHC) to analyze
a human breast tissue microarray (TMA) and to systematically
catalogue the prevalence of both membrane-associated and
nucleocytoplasmic ß-catenin protein. We sought to characterize
the status of Wnt/ß-catenin signaling as a function of breast cancer
progression by quantifying and comparing the proportion of tissue
samples that exhibited nucleocytoplasmic ß-catenin in benign
breast tissue, ductal carcinoma in situ tumors, and invasive
carcinomas. An additional goal was to assess the relationship
between canonical Wnt pathway activation and HER2 overex-
pression based on several lines of evidence indicating that Wnt and
epidermal growth factor receptor (EGFR) signaling pathways can
interact [33–42]. Data presented herein suggest that Wnt/ß-
catenin pathway activation may be an early event in breast
neoplasia, and may be driven, at least in part, by HER2/neu
expression.
Materials and Methods
Ethics Statement
All mice were housed in pathogen-free rooms in filter-topped
cages at the Laboratory Animal Research Center at the New York
Blood Center. This facility is accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care, and
operates in accordance with Federal (PHS Policy on the Human
Care and Use of Animals, Guide for the Use and Care of
Laboratory Animals, Animal Welfare Act), State and local laws
and regulations. All mice were used in accordance with protocols
approved by the Institutional Animal Care and Use Committees of
both the New York Blood Center (Protocol Number 266) and
Weill Cornell Medical College (Protocol Numbers 0808-787A,
0055-11). Mice received food and water ad libitum.
Tissue Microarray
To analyze ß-catenin protein immunohistochemically in human
breasttissueswe used the2
nd GenerationBreastCancerProgression
Tissue Microarray developed by the National Cancer Institute
(NCI) Cancer Diagnosis Program (CDP). The CDP assembled a
collection of 339 breast tissue specimens arrayed on three separate
slides (http://cdp.nci.nih.gov/breast/progression_cs2.html). The
intended tissue representation was: 69 cores of benign breast tissue
(normal or hyperplastic), 31 ductal carcinoma in situ (DCIS)
specimens, and 239 invasive breast cancers with a principal
histology of ductal carcinoma. Of the benign samples, 43 were
from women without breast cancer and 26 were from individuals
with breast cancer represented elsewhere on the TMA. Of the
DCIS samples, 15 were from women without breast cancer and 16
were from individuals with breast cancer represented elsewhere on
the TMA. Of the invasive carcinomas, there were 80 from patients
that were node-negative at diagnosis, 80 from patients that were
node-positive but not metastatic at diagnosis, and 79 from patients
with metastatic disease at diagnosis. The TMA slides purchased
from the NCI CDP contained coded human biological specimens
lacking personal identifiers such that they could not be linked to
specific individuals by the research team. Therefore this study did
not constitute human subjects research, and Institutional Review
Board approval was not required.
Three freshly-cut serial sections were obtained from each of the
three TMA blocks. Two of the three sections from each block were
stained in duplicate for ß-catenin protein by IHC as described
below. The third intermediate section was stained in parallel
omitting primary antibody to provide a negative control.
Histopathology of each core on slides stained with ß-catenin
antibody was evaluated by a breast pathologist (D.D.G.).
Immunohistochemistry Staining and Scoring
ß-catenin IHC was performed using Clone 14 anti-ß-catenin
antibody (BD Transduction Labs) as previously described [43].
Scoring was completed by a specialist breast pathologist (D.D.G.)
and a scientist (L.R.H.) blinded to the clinical information;
consensus was reached by simultaneous examination using a dual-
headed microscope. ß-catenin signal intensity was separately
scored in two cellular compartments, membrane and nucleocyto-
plasmic, which represent distinct functional pools of ß-catenin.
The scoring system for each compartment was: 0, no ß-catenin
staining; +/2, weak signal; 1+, clear uniform signal; 2+, strong
uniform signal; 3+, extremely strong uniform signal. Mean values
for each sample were generated from the data for duplicate cores.
Membrane and nucleocytoplasmic signals were considered
separately when assessing correlations with clinicopathological
parameters. For this purpose, cores were assigned as negative
(score=0) or positive (score=+/2,1 +,2 + or 3+) for each
functional pool of ß-catenin.
HER2 IHC was performed on an additional set of TMA slides
by the MSKCC Pathology Dept using Ventana’s PATHWAY
anti-HER2 antibody (clone 4B5), an FDA-approved monoclonal
for immunohistochemical detection of HER2 protein in breast
cancer tissue. Slides were scored by a breast pathologist (D.D.G.)
in accordance with the American Society of Clinical Oncology/
College of American Pathologists guideline recommendations for
HER2 testing in breast cancer [44].
Mouse strains, breeding, tissue harvesting and
processing
MMTV/NDL mice express a mammary-targeted, mutationally
activated HER2/neu allele (NDL, Neu Deletion mutant), under the
control of the mouse mammary tumor virus (MMTV) long
terminal repeat, that induces mammary hyperplasia and tumor-
igenesis [45]. Tissue sections were prepared from formalin-fixed,
paraffin-embedded MMTV/NDL mammary glands (MGs) gen-
erated during a previous study [46], and were subjected to ß-
catenin IHC as described above.
The Axin2
NLSlacZ strain (Axin2LacZ) provides a useful reporter of
in vivo ß-catenin/TCF signaling. Axin2 is upregulated in response
to canonical Wnt/ß-catenin signaling, and functions as a negative
Wnt/b-Catenin Signaling and Breast Ca Progression
PLoS ONE | www.plosone.org 2 March 2012 | Volume 7 | Issue 3 | e33421feedback regulator [47,48]. Axin2
NLSlacZ mice have a bacterial ß-
galactosidase (ß-gal; LacZ) expression cassette ‘‘knocked-in’’ to the
endogenous Axin2 locus, such that ß-gal activity provides a
surrogate for Wnt/ß-catenin signaling [48]. We have previously
established that this strain functions appropriately as a reporter of
in vivo ß-catenin/TCF pathway activation in mouse mammary
gland by demonstrating increased ß-gal activity in response to
expression of a Wnt1 transgene [43].
The MMTV/neu strain (FVB/N-Tg(MMTVneu)202Mul/J; The
Jackson Laboratory) expresses a wildtype HER2/neu allele.
MMTV/neu females develop palpable mammary tumors with a
latency of 2–18 months, with subsequent lung metastases [49].
Mammary tumors in this strain bear mutationally activated alleles
of the HER2/neu transgene, suggesting that mutational activation of
the transgene may be a prerequisite for tumor formation [45,50].
Here, Axin2
+/NLSlacZ mice were interbred with homozygous
MMTV/neu animals. Abdominal (#4) mammary glands were
harvested post-mortem from both MMTV/neu and bigenic
MMTV/neu, Axin2
+/NLSlacZ female offspring, stained with X-gal
to detect ß-gal activity and wholemounted, as previously described
[43]. Abdominal MGs from Pea3
NLSlacZ females were harvested
and stained in parallel to provide a positive control for LacZ
staining. Pea3
NLSlacZ mice (Pea3LacZ) have a ß-gal expression
cassette ‘‘knocked-in’’ to the endogenous Pea3 gene, which is
expressed predominantly in the myoepithelial compartment in
murine mammary gland [43,51]. Genotyping of Axin2LacZ and
Pea3LacZ mice was performed as described previously [43].
Data Analysis
In this study, the proportion of samples with positive membrane
and nucleocytoplasmic ß-catenin staining in samples of various
clinical pathological categories were summarized and compared.
Specifically, the associations between ß-catenin staining and the
type of tissue sample were examined using mixed-effects logistic
regression to take into account possible within-subject correlation
because some subjects provided samples of more than one tissue
type. Pair-wise comparison of ß-catenin staining positivity between
any two tissue types of interest were performed using simultaneous
inference methods for general parametric models [52]. P-values
were adjusted for multiple comparisons using the conservative
Bonferroni method. Fisher’s exact test was used to examine the
association between ß-catenin staining and clinicopathological
parameters within the invasive cancer cases, and to explore the
association between membrane and nucleocytoplasmic ß-catenin
in samples of the same tissue type.
Results
In this study, we used IHC to assess ß-catenin protein levels in
human breast tissues on the 2
nd Generation Breast Cancer
Progression TMA generated by the NCI Cancer Diagnosis
Program (see Materials and Methods for composition of the
TMA set). Meaningful data were obtained from 90% of the 339
cores (Table 1). 19 cores did not contain the stated tissue type, and
were excluded from subsequent analyses. A further 15 cores were
not assessable because of poor sample integrity. Therefore only
305 cores were further analyzed. Notably, although 97% of the
invasive breast cancer cores (231/239) yielded data, only 58% of
DCIS cores (18/31) were assessable. Clinical characteristics of the
assessed invasive breast cancer cases are summarized in Table 2.
We independently scored the signal intensities for two discrete
functional pools of ß-catenin, membrane (MB) and nucleocyto-
plasmic (NC), for each core. Nuclear and cytoplasmic signals were
combined into a single entity because accumulation at both these
subcellular locations is indicative of canonical Wnt signaling
pathway activation. Strikingly in this respect, Kim et al. reported
an absolute correlation between nuclear and cytosolic ß-catenin
protein levels in all of nine breast cancer cell lines tested using a
systematic fractionation approach [53]. In our study, ß-catenin
signals were detected predominantly in epithelial cells, with
negligible staining of stromal components. Normal colon tissue
included on the TMA served as a positive control for ß-catenin
staining. As expected, colonocytes exhibited distinct membrane
staining, with no cytoplasmic or nuclear staining (Figure 1A). We
anticipated that normal breast tissues would similarly exhibit
membrane-localized ß-catenin, given that ß-catenin is an impor-
tant junctional component in epithelial tissues. However, only
82% of benign breast samples (46/56) had detectable membrane
staining (e.g. Figure 1B), with a mode value of +/2 (Figure 2A),
and almost one-fifth of benign breast tissues (n=10) had essentially
no detectable membrane signal despite exhibiting overtly normal
epithelial morphology (e.g. Figure 1C).
In DCIS tumors the frequency of positive membrane ß-catenin
staining was similar to that in benign breast tissue (89% vs. 82%;
P=0.72) (Figure 2A; Table 3). In contrast, the proportion of
invasive breast cancers with membrane positivity was significantly
decreased: only 45% of invasive samples (104/231) exhibited
detectable membrane ß-catenin (P,0.001 compared with either
benign or DCIS). Additionally, when cases were sub-divided into
Table 1. TMA composition and quality.
Tissue Type Benign DCIS Invasive ALL
Total no. of cores 69 31 239 339
No. of cores with incorrect tissue 7 7 5 19
No. of unassessable cores 6 6 3 15
No. of data-yielding cores 56 18 231 305
Percent data-yielding cores 81% 58% 97% 90%
doi:10.1371/journal.pone.0033421.t001
Table 2. Clinical characteristics of breast cancer patients.
Characteristic Subcategory Data
Age at diagnosis, mean6SD 60.5614.3 years
a
Race, n (%) White 200 (87%)
Black 28 (12%)
Other 3 (1%)
Grade, n (%) I 38 (17%)
II 103 (46%)
III 83 (37%)
AJCC T stage, n (%) 1 106 (46%)
2 96 (42%)
3 10 (4%)
4 19 (8%)
Metastasis, n (%) 77 (33%)
Tumor size, mean6SD 2.861.9 cm
Lymph node involvement, n (%) 110 (58%)
b
aTotal number of patients=231.
bNodal status unavailable for 41 cases with distant metastasis.
doi:10.1371/journal.pone.0033421.t002
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lower odds of having positive membrane staining in higher stage
cancer was observed (Table 3). Examples of invasive cancer
staining patterns are shown in Figure S1.
Nucleocytoplasmic staining was not detected in the majority of
benign breast samples (Figure 2B). However, approximately one
quarter had a +/2 nucleocytoplasmic score (15/56), and five
samples had stronger staining (e.g. Figure 1D). In total,
nucleocytoplasmic staining was detected in 36% (20/56) of benign
samples (Table 3; Figure 2B). These findings contrasted with our
expectation that benign breast tissue would exhibit little or no
nucleocytoplasmic ß-catenin. Similar frequencies of nucleocyto-
plasmic ß-catenin were observed in invasive carcinomas (82/231;
35%; P=1). Interestingly however, the proportion of DCIS
tumors positive for nucleocytoplasmic ß-catenin was quantitatively
increased relative to benign tissue (10/18; 56%; Figure 2B;
Table 3) (e.g. Figure 1F).
A striking positive correlation was identified between membrane
and nucleocytoplasmic ß-catenin positivity in individual samples
(Table 4). For carcinoma cores, having positive ß-catenin
membrane staining increased the odds of having positive
nucleocytoplasmic signal in the same core by 15-fold (95%
CI=(7.3, 32.6), P,0.001, Fisher’s exact test). The two parameters
were not associated in DCIS cores, but there was a correlation
between membrane and nucleocytoplasmic ß-catenin positivity in
benign breast tissue samples (P=0.01, Fisher’s exact test). In order
to control for effects of this correlation, we conducted an
additional analysis restricted to those samples with positive
membrane staining (n=166). In this subset, the proportion of
samples with positive nucleocytoplasmic staining was increased for
both DCIS (56%, 9/16) and invasive cancer samples (65%, 68/
104; P=0.03) relative to benign breast tissue (43%, 20/46).
Associations between ß-catenin signal and clinicopathological
parameters were assessed for the invasive cancer cases (Table 5).
Decreased membrane ß-catenin positivity was associated with
higher grade (P=0.04) and estrogen receptor (ER) negative status
(P=0.03), both indices of poor prognosis. No statistically
significant associations were observed between nucleocytoplasmic
ß-catenin positivity and individual clinicopathological parameters
when all invasive tumors were considered together (Table 5).
However, stratification into node-negative, node-positive and
metastatic revealed an association between nucleocytoplasmic ß-
catenin and HER2/neu positivity in node-positive cases. Nucleo-
cytoplasmic ß-catenin was detected in 67% (8/12) of HER2/neu-
expressing node-positive breast carcinomas, but only in 30% (20/
66) of HER2/neu-negative node-positive cases (P=0.02). When
all invasive cases were considered together, the data were also
suggestive of a potential interaction between HER2/neu and ß-
catenin stabilization: nucleocytoplasmic ß-catenin was detected in
43.8% of HER2/neu-expressing breast carcinomas, but only in
34.2% of HER2/neu-negative cases (Table 5; not significant). In
DCIS tumors, 100% of HER2/neu-positive cases (3/3) exhibited
nucleocytoplasmic ß-catenin, whereas only 50% of HER2/neu-
negative samples (7/14) were nucleocytoplasmic ß-catenin-posi-
tive, but statistical power was limited by small sample size.
To further investigate the potential relationship between
HER2/neu and canonical Wnt signaling in vivo in mammary
tissues, we assessed ß-catenin localization and function in
mammary glands (MGs) from HER2/neu transgenic mice. Firstly,
ß-catenin IHC was performed on MG sections from MMTV/
NDL mice, which develop multiple DCIS-like lesions in each MG
due to expression of a mammary-targeted, mutationally activated
HER2/neu allele [45,46]. Diffuse cytoplasmic ß-catenin staining
was observed in DCIS lesions in MMTV/NDL MGs (Figure 3),
Figure 1. ß-catenin staining patterns of benign human tissues.
The 2
nd Generation Breast Cancer Progression TMA purchased from the
NCI Cancer Diagnosis Program was subjected to ß-catenin IHC using BD
Transduction Labs anti-ß-catenin antibody Clone 14 as previously
described [43] and counterstained with hematoxylin. As a control, serial
sections were stained in parallel omitting primary antibody (right-hand
panels). (A) Normal colon. (B–E) Normal breast. (F) Ductal carcinoma in
situ. The image in (E) illustrates the positive nuclear ß-catenin staining
observed in myoepithelial cells in some benign breast cores (inset,
enlargement of boxed area; red arrowheads indicate positively-staining
nuclei).
doi:10.1371/journal.pone.0033421.g001
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PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e33421Figure 2. ß-catenin signal as a function of breast cancer progression. Each core was assigned a separate score (0, +/2,1 +,2 +,o r3 +) for
membrane ß-catenin signal (A) and nucleocytoplasmic ß-catenin signal (B), and the percentage of cores with each score was separately calculated for
benign breast tissue, DCIS, and invasive carcinomas. Of note, the staining pattern denoted as +/2 in this study appeared visually similar to the
staining pattern scored as 1 by Khramtzov and colleagues [27]. A statistically significant reduction in membrane signal was observed in invasive
cancers relative to benign breast tissues (P,0.001). A numerical increase in the proportion of DCIS tumors with nucleocytoplasmic ß-catenin
compared with normal breast tissue was observed.
doi:10.1371/journal.pone.0033421.g002
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Stage MB ß-catenin (pos/total) MB-positive (%) P
a NC ß-catenin (pos/total) NC-positive (%) P
a
Benign 46/56 82.1% 20/56 35.7%
DCIS 16/18 88.9% 0.51 10/18 55.6% 0.13
Node-Neg 39/76 51.3% ,0.001 30/76 39.5% 0.67
Node-Pos 32/78 41.0% ,0.001 28/78 35.9% 0.99
Metastatic 33/77 42.9% ,0.001 24/77 31.2% 0.56
aP-values were obtained using mixed-effects logistic regression with Benign cases as the reference.
doi:10.1371/journal.pone.0033421.t003
Table 4. Correlations between membrane and nucleocytoplasmic ß-catenin in individual cores.
Tissue Type MB ß-catenin Status NC ß-catenin negative/total (%) NC ß-catenin positive/total (%) P
a
Benign Negative 10/10 (100%) 0/10 (0%) 0.01
Positive 26/46 (56.5%) 20/46 (43.5%)
DCIS Negative 1/2 (50%) 1/2 (50%) 1
Positive 7/16 (43.8%) 9/16 (56.3%)
Invasive Negative 113/127 (89%) 14/127 (11%) ,0.001
Positive 36/104 (35%) 68/104 (65%)
aP-values were obtained using Fisher’s exact test.
doi:10.1371/journal.pone.0033421.t004
Table 5. Clinicopathologic association of ß-catenin expression in patients with invasive cancer.
Parameter Subcategory
MB ß-catenin (pos/
total) MB-positive (%) P
NC ß-catenin (pos/
total) NC-positive (%) P
Age (yr) ,50 25/56 44.6 22/56 39.3
$50 79/175 45.1 1 60/175 34.3 0.52
Tumor size #2 cm 52/108 48.1 39/108 36.1
.2 cm 52/123 42.3 0.43 43/123 35.0 0.89
Node Status Negative 38/80 47.5 31/80 38.8
Positive 43/110 39.1 0.30 33/110 30.0 0.22
Metastasis Negative 71/154 46.1 58/154 37.8
Positive 33/77 42.9 0.68 24/77 31.2 0.38
Grade I 16/38 42.1 9/38 23.7
II 55/103 53.4 38/103 36.9
III 29/83 34.9 0.04
a 32/83 38.9 0.26
ER Negative 23/68 33.8 22/68 32.4
Positive 80/160 50.0 0.03 59/160 36.9 0.55
PR Negative 53/118 44.9 46/118 39.0
Positive 49/108 45.4 1 35/108 32.4 0.33
HER2 Negative 90/199 45.2 68/199 34.2
Positive 14/32 43.8 1 14/32 43.8 0.32
aOverall difference across the three groups. Pairwise comparisons showed significant difference between Grade III cases and Grade II cases (P. adj=0.05, P values
adjusted for multiple comparisons using Bonferroni method).
doi:10.1371/journal.pone.0033421.t005
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tumors (Figure 1F). This staining pattern contrasted with the
predominantly membranous signal that we observed in mammary
epithelium from wildtype mice [43].
To test the in vivo functional significance of HER2/neu-induced
ß-catenin redistribution, we employed a ß-catenin/TCF reporter
strain, Axin2
NLSlacZ, which has a ß-gal expression cassette
‘‘knocked-in’’ to the Axin2 locus [48]. We previously established
the utility of this strain for detecting ß-catenin/TCF-dependent
transcription in mouse mammary gland by demonstrating
dramatically increased ß-gal reporter activity in Axin2
NLSlacZ
MGs in response to expression of Wnt1, which activates canonical
Wnt signaling [43]. In the present study, we analyzed MGs from
bigenic MMTV/neu, Axin2
+/NLSlacZ mice, to test the ability of
HER2/neu to drive ß-catenin/TCF-dependent transcription in
vivo. Discrete regions of robust ß-gal activity were detected in the
mammary epithelium of bigenic MMTV/neu, Axin2
+/NLSlacZ MGs
which coincided with focal regions of hyperplasia (Figure 4A–G).
Positively staining regions were of similar size in all cases, with
clearly demarcated boundaries (e.g. Figure 4A–D, F, G; marked
by red arrowheads). The cellular staining profile contrasted
markedly with that detected in Pea3
+/NLSLacZ mice (Figure 4H),
in which ß-gal expression is predominantly restricted to the
myoepithelial layer [43,51]. Comparison of these staining patterns
(e.g. Figure 4G vs 4H) suggests that the Axin2LacZ-positive nuclei
in bigenic MMTV/neu, Axin2
+/NLSlacZ MGs correspond to luminal
epithelial cells, the compartment in which the neu transgene is
expressed.
Discussion
In this study we analyzed ß-catenin protein levels in membrane
and nucleocytoplasmic compartments in human breast tissues
(normal breast, DCIS and invasive cancers) with the goal of better
understanding the activation status of Wnt/ß-catenin signaling in
human breast cancer, given conflicting findings from previous
studies [19,22–32]. Membrane ß-catenin, a key component of
adherens junctions, was undetectable in almost one fifth of normal
breast tissue cores despite overtly normal epithelial morphology
(Figure 2A), suggesting a substantial inherent frequency of false
negatives which may reflect loss of ß-catenin antigenicity during
tissue processing or storage. Of note, we observed a marked
correlation between positivity for membrane and nucleocytoplas-
mic ß-catenin in individual cores of normal breast tissue (Table 4),
again consistent with reduced ß-catenin antigenicity in some
samples. This systematic analysis of normal breast tissues stained
simultaneously on a TMA highlights the potential for underesti-
mating ß-catenin signal in IHC-based analyses. Nevertheless, we
observed a significantly higher frequency of samples lacking
discernible membrane ß-catenin among the invasive cores relative
to the benign breast samples (55% versus 18%; P,0.001 versus
benign), consistent with previous reports of reduced membranous
ß-catenin in human breast cancers [23,25,27,29,54,55]. Loss of
adherens junctions has been suggested to contribute to the invasive
phenotype [56,57]. Consistent with this model, there were
significant correlations between reduced frequencies of membrane
ß-catenin in carcinoma samples and two indices of poor prognosis,
higher grade (P=0.04) and ER-negative status (P=0.03).
In light of the fact that nucleocytoplasmic ß-catenin is indicative
of activated Wnt/ß-catenin signaling, our analysis of nucleocyto-
plasmic ß-catenin signal yielded somewhat unexpected data.
Specifically, we observed a finite frequency of positive nucleocy-
toplasmic staining in normal human breast tissues (36%), with 5 of
the 56 assessable cores exhibiting substantial signal (Figs. 1D &
2B). These findings contrast with a recent study which did not
detect significant nucleocytoplasmic ß-catenin in normal breast
[27]. We hypothesized that Wnt/ß-catenin pathway activation
observed in benign breast tissue could result from precancerous
changes in morphologically normal breast, and further reasoned
that breast tissue adjacent to invasive tumors would be more likely
to contain such protumorigenic molecular alterations. However,
the frequency of nucleocytoplasmic ß-catenin positivity was similar
in benign tissue irrespective of the presence or absence of adjacent
invasive disease (with invasive disease, 31.6% NC-positive; without
invasive disease, 37.8% NC-positive, P=0.77). Thus the basis for
ß-catenin stabilization in these samples remains unclear. Notably,
the vast majority of previous IHC studies of ß-catenin in breast
cancer focused exclusively on malignant specimens.
Intriguingly, some benign breast cores exhibited discrete
staining of nuclei in the basal layer of normal-looking epithelium
(e.g. Figure 1E, inset, arrowheads). This could reflect pathway
activation in these cells by endogenous Wnt ligands, since several
Wnt genes are expressed in human and mouse breast tissues [58].
Figure 3. ß-catenin stabilization is evident in mammary precancers in HER2/neu transgenic mice. Mammary gland tissue sections from
virgin female MMTV/NDL mice were subjected to ß-catenin IHC as previously described [43] and counterstained with hematoxylin. As a control, serial
sections were stained in parallel omitting primary antibody (right-hand panel). Diffuse cytoplasmic ß-catenin was detected in DCIS-like lesions in
MMTV/NDL MGs.
doi:10.1371/journal.pone.0033421.g003
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transgenically expressed Wnt1 ligand in vivo in mouse MG is
predominantlyrestricted tothemyoepithelial compartment[43,59],
reflecting the myoepithelial expression profile of Wnt co-receptors
low density lipoprotein receptor-related protein (LRP) 5 and 6 in
post-natal MG [60,61]. The basally restricted expression pattern of
LRP5/6 may also provide a partial explanation for the observation
that nucleocytoplasmic ß-catenin accumulation is selectively
enriched in basal-like breast cancers [19,27].
We speculate that cells positive for nucleocytoplasmic ß-catenin
in the myoepithelial layer may include mammary stem cells, based
both on location and on substantial data implicating canonical
Wnt signaling in stem cell maintenance [2,3,62]. Intriguingly,
Zeng and Nusse recently reported evidence for active Wnt/ß-
catenin signaling in a subset of basally-located epithelial cells in
murine MG which may overlap with the mammary stem cell
compartment [63]. Further evidence for a relationship between
‘‘stemness’’ and Wnt signaling is provided by the recently reported
association between nuclear/cytoplasmic ß-catenin and the
putative stem cell surface marker phenotype CD44
+/CD24
2 in
human breast carcinomas [27].
In our study, DCIS tumors exhibited the highest frequency of
nucleocytoplasmic ß-catenin. Our analysis of Wnt signaling in
DCIS was limited by the number of samples that yielded
meaningful data (n=18; Table 1). Nevertheless, we saw a
substantially increased frequency of nucleocytoplasmic ß-catenin
positivity in DCIS cores relative to that in benign breast samples
(56% v. 36%) (Figure 2B, Table 3), suggesting the possibility that
Wnt/ß-catenin signaling is activated early during breast neoplasia
and could be a target for prophylactic intervention as in colorectal
cancer [64].
In invasive carcinomas, we detected nucleocytoplasmic ß-
catenin in 35% of samples (Figure 2B), which is within the range
detected in other studies [19,22–28,65]. Notably, and consistent
with observations from other investigators [25,30,31,54], we did
not see profound levels of nuclear ß-catenin comparable to those
reported for colorectal cancers (Figure S1). The intense nuclear
signal commonly observed in colorectal tumors may reflect a
specific response to APC mutation, the causal event in the majority
of human colorectal cancers. In contrast, commensurate increases
in nuclear and cytoplasmic pools are frequently elicited by other
stimuli of the Wnt/ß-catenin pathway, including Wnt1 transgene
expression in mouse MG [43]. Intriguingly, marked cytosolic
accumulation of ß-catenin was observed in mitotic cells in some
carcinoma samples (Figure S1G, inset), consistent with published
data implicating ß-catenin in mitosis [66–69].
No correlations were detected between pathway activation and
any clinicopathological parameter, when invasive cancers were
analyzed as a single population. However, a positive correlation
between HER2/neu expression and nucleocytoplasmic ß-catenin
was observed in node-positive cases (P=0.02). It is unclear
whether this reflects an intrinsic biologic phenomenon specific to
the node-positive subset. Nevertheless, the observed association is
of particular interest because EGFR family members have the
capacity to modulate ß-catenin phosphorylation, localization and
transcriptional activity [33–40]. In apparent contradiction, other
investigators have reported an inverse correlation between HER2/
neu expression and nuclear/cytosolic ß-catenin [19,27]. Con-
versely, Lopez-Knowles and colleagues identified a relationship
between increased cytoplasmic ß-catenin and HER2/neu positiv-
ity [28].
To further investigate the relationship between HER2/neu
expression and canonical Wnt signaling, we analyzed mammary
tissues from HER2/neu transgenic mice. Consistent with our
Figure 4. Discrete hyperplastic foci with robust ß-catenin/TCF
signaling activity are present in MMTV/neu mouse mammary
glands. Abdominal (#4) mammary glands were harvested post-
mortem from virgin female mice that were MMTV/neu or bigenic
MMTV/neu, Axin2
+/NLSlacZ. MGs were stained with X-gal and whole-
mounted as previously described [43]. Pea3
+/NLSlacZ (Pea3LacZ) samples
were processed in parallel for comparison. (A–D) Wholemounted
glands from bigenic MMTV/neu, Axin2
NLSlacZ mice (38–44 weeks old),
viewed at 46magnification. (E,F) Higher power images of lesion seen
in Panel A, viewed at 206 magnification. (G) Higher power image of
lesion seen in Panel C, viewed at 206magnification. (H) Wholemounted
gland from Pea3
+/NLSlacZ virgin female (39 weeks old) stained in parallel
with the specimen in Panels C/G, viewed at 206 magnification. Eight
focal lesions displaying intense ß-gal activity, all of similar size, were
identified in MGs from 26 bigenic MMTV/neu, Axin2
+/NLSlacZ mice. By
contrast, no comparable lesions were observed in MGs from MMTV/neu
mice lacking the Axin2LacZ allele (not shown). Additionally, in our
previous study of Axin2LacZ mice, no such lesions were observed in
tissues from Axin2LacZ animals lacking a tumor-promoting transgene
[43]. Strikingly, each discrete region of robust ß-gal activity in bigenic
MMTV/neu, Axin2
NLSlacZ MGs coincided with a focus of hyperplastic
morphology markedly dissimilar to the normal-looking morphology of
the immediately adjacent ductal structures. Also notable were the
clearly demarcated boundaries between positive and negatively stained
epithelium (examples are marked with red arrowheads in Panels A, C, F,
G). The cellular staining profile in bigenic MMTV/neu, Axin2
NLSlacZ MGs
contrasted with the myoepithelial pattern characteristic of Pea3LacZ
MGs (compare Panels G and H), suggesting that Axin2LacZ is expressed
in luminal cells within the HER2/neu-induced hyperplastic lesions.
doi:10.1371/journal.pone.0033421.g004
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catenin in human DCIS relative to benign breast epithelium
(Figure 2B; Table 3), we detected nucleocytoplasmic ß-catenin in
murine mammary DCIS tumors induced by overexpression of a
mutationally activated HER2/neu transgene (NDL; Figure 3).
Functional significance of nucleocytoplasmic ß-catenin in HER2/
neu-overexpressing breast neoplasias was suggested by data
obtained using the Axin2LacZ reporter strain, a validated tool for
visualizing ß-catenin/TCF signaling in vivo in murine breast tissue.
Discrete regions of intense ß-gal reporter activity were observed to
colocalize with foci of hyperplastic epithelium in MGs from
bigenic MMTV/neu, Axin2LacZ mice (Figure 4A–G). Notably, all
lesions were approximately similar in size and had clearly
delineated boundaries, leading us to speculate that these
hyperplastic foci with robust ß-catenin/TCF signaling could
represent clonal populations with distinct biology from the
immediately adjacent ductal epithelium. Importantly in this
respect, formation of mammary tumors in the MMTV/neu strain
is associated with mutational activation of the (initially) wildtype
neu transgene, which may be an obligate prerequisite to tumor
formation [45,50]. Thus, we speculate that the hyperplastic foci
that we observed may be clonal groups of cells bearing a mutated
neu allele, and potentially the earliest manifestation of mammary
intraepithelial neoplasia (MIN) in this strain. Irrespective of the
mutational status of the neu allele, these observations provide
intriguing evidence of ß-catenin/TCF transcriptional activity in
HER2/neu-expressing MIN lesions, and suggest that HER2/neu-
induced activation of canonical Wnt signaling may be an early
event in breast neoplasia. Consistent with this model, the elevated
frequency at which nucleocytoplasmic ß-catenin was detected in
human DCIS specimens compared with invasive carcinomas in
our study could reflect the relatively high frequency of HER2/neu
overexpression in human DCIS lesions compared with frank
cancers [70–72].
In summary, in this study we effected a systematic comparison
of membrane and nucleocytoplasmic ß-catenin during breast
cancer progression from benign breast to metastatic carcinoma. A
limitation of the study was that outcome data were not available
for the breast cancer cases, and thus prognostic significance of
membrane and nucleocytoplasmic ß-catenin positivity could not
be determined. However, data addressing prognostic significance
has been provided by other studies [19,23,27,28]. Nevertheless, we
made several notable findings, including identification of a
substantial frequency of canonical Wnt signaling pathway
activation in benign human breast tissues, an apparent increase
in pathway activation in DCIS tumors, and a correlation between
HER2/neu expression and nucleocytoplasmic ß-catenin in node-
positive breast carcinomas. A causal relationship between HER2/
neu and Wnt/ß-catenin signaling is suggested by our companion
mouse studies. We observed ß-catenin accumulation in HER2/
neu-induced mouse mammary tumors, and identified discrete
regions of ß-catenin/TCF transcriptional activity coincident with
early MIN lesions in HER2/neu transgenic breast. Our study thus
provides provocative evidence for Wnt/ß-catenin signaling as an
early, HER2/neu-inducible event in breast neoplasia.
Supporting Information
Figure S1 ß-catenin staining patterns of human breast
carcinomas. Images of seven invasive cancer cores demonstrat-
ing the range of observed staining patterns. Samples were scored
as follows: (A) Membrane (MB), 0; Nucleocytoplasmic (NC), 0. (B)
MB, +/2; NC, 0. (C) MB, 1+; NC, 0. (D) MB, 1+; NC, 1+.( E)
MB, 2+; NC, 2+.( F) MB, 0; NC, 2+. The image in (G) illustrates
the positive cytoplasmic ß-catenin staining observed in mitotic cells
in some cores (inset, enlargement of boxed area). Left-hand panels;
slides treated with primary (anti-ß-catenin) and secondary
antibodies; right-hand panels, negative control slides treated with
secondary antibody alone.
(TIF)
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